CN101005829A - 喹硫平制剂 - Google Patents

喹硫平制剂 Download PDF

Info

Publication number
CN101005829A
CN101005829A CNA2004800383272A CN200480038327A CN101005829A CN 101005829 A CN101005829 A CN 101005829A CN A2004800383272 A CNA2004800383272 A CN A2004800383272A CN 200480038327 A CN200480038327 A CN 200480038327A CN 101005829 A CN101005829 A CN 101005829A
Authority
CN
China
Prior art keywords
quetiapine
dosage form
hours
pharmaceutically acceptable
hemifumarate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800383272A
Other languages
English (en)
Chinese (zh)
Inventor
加思·勃姆
约瑟芬·丹敦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actavis Group PTC ehf
Original Assignee
Actavis Group PTC ehf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actavis Group PTC ehf filed Critical Actavis Group PTC ehf
Publication of CN101005829A publication Critical patent/CN101005829A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNA2004800383272A 2003-10-21 2004-10-21 喹硫平制剂 Pending CN101005829A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51346103P 2003-10-21 2003-10-21
US60/513,461 2003-10-21

Publications (1)

Publication Number Publication Date
CN101005829A true CN101005829A (zh) 2007-07-25

Family

ID=34549280

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800383272A Pending CN101005829A (zh) 2003-10-21 2004-10-21 喹硫平制剂

Country Status (7)

Country Link
US (2) US20050158383A1 (cg-RX-API-DMAC7.html)
EP (1) EP1689367A1 (cg-RX-API-DMAC7.html)
JP (1) JP2007509155A (cg-RX-API-DMAC7.html)
CN (1) CN101005829A (cg-RX-API-DMAC7.html)
CA (1) CA2542836A1 (cg-RX-API-DMAC7.html)
IS (1) IS8460A (cg-RX-API-DMAC7.html)
WO (1) WO2005041935A1 (cg-RX-API-DMAC7.html)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011103718A1 (zh) * 2010-02-26 2011-09-01 上海沪美医药科技有限公司 一种含有喹硫平的控(缓)释制剂及其制备方法和用途
CN103211794A (zh) * 2012-01-18 2013-07-24 北京天衡药物研究院 富马酸喹硫平膜控缓释微丸胶囊
CN104523600A (zh) * 2014-11-21 2015-04-22 哈尔滨圣吉药业股份有限公司 一种富马酸喹硫平缓释微丸及其制备方法
CN104546800A (zh) * 2015-01-07 2015-04-29 万特制药(海南)有限公司 一种富马酸喹硫平缓释胶囊及其制备方法
CN114582457A (zh) * 2020-11-30 2022-06-03 国际商业机器公司 时间控制的药物

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050171088A1 (en) * 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic
WO2006081347A2 (en) * 2005-01-26 2006-08-03 Elan Pharma International Limited Controlled release compositions comprising an antipsychotic agent
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
DK1808164T3 (da) 2006-01-05 2009-04-20 Teva Pharma Vådgranuleringsmetode til fremstilling af farmaceutiske sammensætninger af aripiprazol
EP1976487A2 (en) * 2006-01-25 2008-10-08 Astron Research Limited Sustained release dosage form of phenothiazine derivatives containing channelizer
DE102006033723A1 (de) * 2006-07-21 2008-01-24 Bayer Technology Services Gmbh Formulierungen von Multikompartimenten-Granulaten für Wirkstoffe
WO2008012346A1 (en) * 2006-07-28 2008-01-31 Farmaprojects, S. A. Extended release pharmaceutical formulation of metoprolol and process for its preparation
GB0618879D0 (en) * 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
US8623861B2 (en) * 2006-11-03 2014-01-07 Xin-Min Li Method of treating demyelination diseases
PT103884A (pt) * 2006-11-17 2008-05-19 Astrazeneca Ab Composições de libertação prolongada e métodos para a sua preparação
EP1958617B1 (en) * 2007-02-14 2010-09-08 Laboratorios Lesvi, S.L. Pharmaceutical compositions containing quetiapine fumarate
EP2131817A2 (en) * 2007-03-09 2009-12-16 Synthon B.V. Pharmaceutical composition of quetiapine fumarate
EP1970056A1 (en) * 2007-03-15 2008-09-17 Polichem S.A. Time-specific delayed/pulsatile release dosage forms
US20090035370A1 (en) * 2007-08-02 2009-02-05 Drugtech Corporation Dosage form and method of use
US20100216754A1 (en) * 2007-11-13 2010-08-26 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US20090143343A1 (en) * 2007-11-13 2009-06-04 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
DK3354276T3 (da) 2007-11-13 2020-03-30 Meritage Pharma Inc Sammensætninger til behandlingen af gastrointestinal inflammation
US20090148532A1 (en) * 2007-12-06 2009-06-11 Venkatesh Gopi M Preparation of controlled release skeletal muscle relaxant dosage forms
US20090220593A1 (en) * 2008-01-29 2009-09-03 Gulati Inder Extended release dosage forms of quetiapine
EP2268283A2 (en) * 2008-03-12 2011-01-05 Dexcel Ltd. Oral modified-release formulations containing thiazepines
AU2009265099A1 (en) * 2008-07-01 2010-01-07 Lupin Limited Sustained release pharmaceutical compositions comprising Quetiapine
AU2009270823B2 (en) 2008-07-16 2014-07-17 Richter Gedeon Nyrt. Pharmaceutical formulations containing dopamine receptor ligands
EP2299983A4 (en) * 2008-07-24 2012-10-10 Handa Pharmaceuticals Llc ATYPICAL ANTIPSYCHOTIC FORMULATION STABILIZED
DE202009018024U1 (de) 2008-08-01 2010-12-09 Krka Tovarna Zdravil, D.D., Novo Mesto Quetiapin-Zusammensetzung
EP2153834A3 (en) * 2008-08-07 2010-02-24 Farmaprojects, S.A. Extended release pharmaceutical compositions comprising quetiapine salts
AU2009289464B2 (en) * 2008-09-04 2015-12-10 Farnam Companies, Inc. Chewable sustained release formulations
DE102008046650A1 (de) 2008-09-10 2010-03-11 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Quetiapin enthaltende Retardtablette
WO2010066342A1 (en) * 2008-11-26 2010-06-17 Krka Quetiapine composition
WO2010082220A2 (en) * 2009-01-05 2010-07-22 Torrent Pharmaceuticals Limited Sustained release pharmaceutical composition of quetiapine and process for preparation thereof
WO2010089259A2 (en) 2009-02-04 2010-08-12 Woerwag R&D Gmbh Sustained release composition containing quetiapine
EP2233130A1 (en) * 2009-03-23 2010-09-29 Genepharm (Europe) Trading Limited A sustained release oral composition of an antipsychotic agent
EP2440210A4 (en) * 2009-06-12 2014-01-29 Meritage Pharma Inc METHOD FOR THE TREATMENT OF STOMACH DARM DISEASES
CN107714703A (zh) 2009-12-31 2018-02-23 凯姆制药公司 喹硫平的氨基酸缀合物、其制备和使用方法
EP2544667B1 (en) * 2010-03-09 2018-11-14 Alkermes Pharma Ireland Limited Alcohol resistant enteric pharmaceutical compositions
RS58335B1 (sr) 2010-03-11 2019-03-29 Kempharm Inc Konjugati kvetiapina sa masnom kiselinom, proces za njihovo dobijanje i njihova primena
EP2588089B1 (en) 2010-04-07 2017-08-30 Kemin Industries, Inc. Micro particles for oral delivery in animals
WO2011132008A2 (en) 2010-04-22 2011-10-27 EGIS Gyűgyszergyár Nyilvánosan Múködő Részvény társaság Controlled release pharmaceutical composition
CA2705685A1 (en) * 2010-05-27 2011-11-27 Pharmascience Inc. Pharmaceutical dosage form containing an antipsychotic agent
WO2011154118A1 (en) * 2010-06-07 2011-12-15 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Quetiapine prolonged-release tablets
DE102010033527A1 (de) 2010-08-05 2012-02-09 Acino Pharma Ag Quetiapin-Tabletten
TR201008261A1 (tr) * 2010-10-08 2012-04-24 Sanovel İlaç San. Ve Ti̇c. A.Ş. Kontrollü salım gerçekleştiren ketiapin formülasyonları
CN102525988B (zh) * 2011-01-04 2016-01-06 北京天衡药物研究院 富马酸喹硫平缓释片
AT511581A1 (de) * 2011-05-26 2012-12-15 G L Pharma Gmbh Orale retardierende formulierung
DE102011115690A1 (de) 2011-10-11 2013-04-11 Acino Pharma Ag Quetiapin enthaltende Formulierungen
WO2013100879A1 (en) * 2011-12-27 2013-07-04 Mahmut Bilgic Pharmaceutical compositions comprising quetiapine
US8912197B2 (en) 2012-08-20 2014-12-16 Forest Laboratories Holdings Ltd. Crystalline form of carbamoyl-cyclohexane derivatives
US20150231080A1 (en) 2012-09-10 2015-08-20 Pharmathen S.A. Pharmaceutical composition comprising an atypical antipsychotic agent and method for the preparation thereof
WO2014155387A1 (en) * 2013-03-24 2014-10-02 Tushar Patel Extended release dosage forms of quetiapine salts
US20160199369A1 (en) * 2013-08-12 2016-07-14 Pharmaceutical Manufacturing Research Services, Inc. Extruded Immediate Release Abuse Deterrent Pill
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
DK3169315T3 (da) 2014-07-17 2020-08-10 Pharmaceutical Manufacturing Res Services In Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
GB201420311D0 (en) 2014-11-14 2014-12-31 Bio Images Drug Delivery Ltd Pharmaceutical processing
GB201420300D0 (en) * 2014-11-14 2014-12-31 Bio Images Drug Delivery Ltd Tablet
GB201420306D0 (en) 2014-11-14 2014-12-31 Bio Images Drug Delivery Ltd Compositions
RU2588840C1 (ru) * 2015-03-26 2016-07-10 Общество с ограниченной ответственностью ООО "ВАЛЕНТА-ИНТЕЛЛЕКТ" Таблетки кветиапина с пролонгированным высвобождением и способ их получения
US20190022013A1 (en) 2015-12-19 2019-01-24 First Time Us Generics Llc Soft-chew tablet pharmaceutical formulations
CN108712900A (zh) * 2015-12-19 2018-10-26 第时间美国泛型药物有限公司 软咀嚼片剂药物制剂
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
US9993486B1 (en) 2017-06-19 2018-06-12 Tlc Therapeutics, Llc Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability
WO2020025579A1 (en) * 2018-07-31 2020-02-06 Medichem, S.A. Solid dosage form of quetiapine fumarate
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
EP4213817A1 (en) * 2020-09-21 2023-07-26 Sun Pharmaceutical Industries Limited Multi-particulate pharmaceutical composition of quetiapine
WO2024086307A1 (en) * 2022-10-19 2024-04-25 Vitakey Inc. Formulated food products
CN120114403B (zh) * 2025-03-12 2025-12-02 上海国创医药股份有限公司 一种富马酸喹硫平缓释组合物及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
JP3628401B2 (ja) * 1995-11-09 2005-03-09 信越化学工業株式会社 無溶媒腸溶性コーティング剤された腸溶性製剤
US20030059471A1 (en) * 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
DE69915346T2 (de) * 1998-12-17 2004-07-22 Alza Corp., Mountain View Umwandlung von flüssigkeitsgefüllten gelatinkapseln in systeme mit gesteuerter wirkstoffabgabe durch mehrfache beschichtungen
WO2003039514A1 (en) * 2001-10-18 2003-05-15 Verion Inc. Microcapsule matrix microspheres, absorption-enhancing pharmaceutical compositions and methods
US20030158254A1 (en) * 2002-01-24 2003-08-21 Xenoport, Inc. Engineering absorption of therapeutic compounds via colonic transporters

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011103718A1 (zh) * 2010-02-26 2011-09-01 上海沪美医药科技有限公司 一种含有喹硫平的控(缓)释制剂及其制备方法和用途
CN102281881A (zh) * 2010-02-26 2011-12-14 上海沪美医药科技有限公司 一种含有喹硫平的控(缓)释制剂及其制备方法和用途
CN103211794A (zh) * 2012-01-18 2013-07-24 北京天衡药物研究院 富马酸喹硫平膜控缓释微丸胶囊
CN104523600A (zh) * 2014-11-21 2015-04-22 哈尔滨圣吉药业股份有限公司 一种富马酸喹硫平缓释微丸及其制备方法
CN104546800A (zh) * 2015-01-07 2015-04-29 万特制药(海南)有限公司 一种富马酸喹硫平缓释胶囊及其制备方法
CN114582457A (zh) * 2020-11-30 2022-06-03 国际商业机器公司 时间控制的药物

Also Published As

Publication number Publication date
JP2007509155A (ja) 2007-04-12
EP1689367A1 (en) 2006-08-16
IS8460A (is) 2006-05-11
US20050158383A1 (en) 2005-07-21
CA2542836A1 (en) 2005-05-12
US20070244093A1 (en) 2007-10-18
WO2005041935A1 (en) 2005-05-12

Similar Documents

Publication Publication Date Title
US20070244093A1 (en) Quetiapine formulations
RU2376988C2 (ru) Фармацевтические композиции замедленного высвобождения, содержащие аплиндор и его производные
US20050191349A1 (en) Galantamine formulations
CN101784266B (zh) 氢溴酸安非他酮以及治疗的应用
US20050163842A1 (en) Rosiglitazone and metformin formulations
US20050163858A1 (en) Ziprasidone formulations
US20050163837A1 (en) Rosiglitazone formulations
WO2005065673A1 (en) Atomoxetine formulations
WO2010008203A2 (ko) 칼슘채널길항제를 포함하는 약제학적 제제
WO2019088669A1 (ko) 붕해가 개선된 경구용 고형 제제 조성물 및 이의 제조 방법
WO2009134086A2 (ko) 심혈관계 질환 치료용 약제학적 제제
WO2013162114A1 (ko) 위체류 약물전달 시스템을 이용한 서방성 제제
US20100104643A1 (en) Pharmaceutical compositions
US20050163843A1 (en) Alprazolam formulations
WO2018111002A1 (ko) 카바메이트 화합물을 포함하는 구강 붕해 정제
WO2018097629A1 (ko) 바레니클린 서방성 제제 및 이의 제조 방법
WO2016060365A1 (ko) 메트포르민 서방성 제제 및 그의 제조방법
US8153159B2 (en) Modafinil modified release pharmaceutical compositions
WO2017146286A1 (ko) 친수성서방폴리머의 매트릭스를 이용한 은행잎 추출물의 약학조성물 및 이를 이용한 경구용 서방성 제제
WO2009125944A9 (ko) 비디히드로피리딘계 칼슘 채널 차단제 및 안지오텐신-2 수용체 차단제를 포함하는 약제학적 제제
EP1791531A1 (en) Paroxetine formulations
WO2009125987A9 (ko) 약제학적 제제
WO2015012633A1 (ko) 서방형 메트포르민과 속방형 HMG-CoA 환원효소 억제제를 포함하는 복합제제
EP3664798B1 (en) Pharmaceutical composition comprising eliglustat
WO2010008224A2 (ko) 안정성이 개선된 암로디핀 속붕해성 정제 및 그의 제조 방법

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication